1. Home
  2. BSII vs PBYI Comparison

BSII vs PBYI Comparison

Compare BSII & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BSII
  • PBYI
  • Stock Information
  • Founded
  • BSII 2024
  • PBYI 2010
  • Country
  • BSII Hong Kong
  • PBYI United States
  • Employees
  • BSII N/A
  • PBYI N/A
  • Industry
  • BSII
  • PBYI Biotechnology: Pharmaceutical Preparations
  • Sector
  • BSII
  • PBYI Health Care
  • Exchange
  • BSII Nasdaq
  • PBYI Nasdaq
  • Market Cap
  • BSII 192.2M
  • PBYI 154.1M
  • IPO Year
  • BSII 2024
  • PBYI N/A
  • Fundamental
  • Price
  • BSII $10.00
  • PBYI $2.98
  • Analyst Decision
  • BSII
  • PBYI Strong Buy
  • Analyst Count
  • BSII 0
  • PBYI 1
  • Target Price
  • BSII N/A
  • PBYI $7.00
  • AVG Volume (30 Days)
  • BSII 11.8K
  • PBYI 386.8K
  • Earning Date
  • BSII 01-01-0001
  • PBYI 05-01-2025
  • Dividend Yield
  • BSII N/A
  • PBYI N/A
  • EPS Growth
  • BSII N/A
  • PBYI 37.78
  • EPS
  • BSII N/A
  • PBYI 0.62
  • Revenue
  • BSII N/A
  • PBYI $230,468,000.00
  • Revenue This Year
  • BSII N/A
  • PBYI N/A
  • Revenue Next Year
  • BSII N/A
  • PBYI $3.27
  • P/E Ratio
  • BSII $104.62
  • PBYI $4.83
  • Revenue Growth
  • BSII N/A
  • PBYI N/A
  • 52 Week Low
  • BSII $9.85
  • PBYI $2.23
  • 52 Week High
  • BSII $10.35
  • PBYI $6.06
  • Technical
  • Relative Strength Index (RSI)
  • BSII N/A
  • PBYI 39.26
  • Support Level
  • BSII N/A
  • PBYI $3.14
  • Resistance Level
  • BSII N/A
  • PBYI $3.18
  • Average True Range (ATR)
  • BSII 0.00
  • PBYI 0.20
  • MACD
  • BSII 0.00
  • PBYI -0.06
  • Stochastic Oscillator
  • BSII 0.00
  • PBYI 4.38

About BSII Black Spade Acquisition II Co Class A Ordinary Share

Black Spade Acquisition II Co is a blank check company.

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Share on Social Networks: